Outstanding measure of efficacy relative to high-risk cancers with limited treatment optionsCHICAGO, (GLOBE NEWSWIRE) -- MAIA ...
The global Biometric Authentication Identification Market was valued at USD 6.5 billion, reflecting the growing reliance on ...
Nurea announced that its PraevAorta 2 software has received FDA 510(k) clearance for the United States market. According to ...
A data breach affecting American medical imaging provider SimonMed Imaging has leaked the personal information of 1.2 million people. SimonMed learned of the data breach on January 7 after a ...
When patients unburden themselves to me in my consulting room, they do so in the knowledge that what they say is confidential. They tell me many things they wouldn’t want others to know: issues that ...
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Com ...
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...
The move follows the state health department’s immediate jeopardy recommendation it sent to federal regulators earlier this ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
Drug Take Back Day returns Oct. 25 in Tuscarawas County. Here’s where to drop off unwanted meds and what not to bring.
Topline data were announced from two phase 3 trials evaluating ulixacaltamide in patients with essential tremor.
Nearly 80% of adults with a previous SARS-CoV-2 infection demonstrated a loss of smell up to 2 years later, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback